ExodusPoint Capital Management LP Has $74.12 Million Holdings in Becton, Dickinson and Company (NYSE:BDX)

ExodusPoint Capital Management LP decreased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 30.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 326,704 shares of the medical instruments supplier’s stock after selling 139,760 shares during the quarter. Becton, Dickinson and Company accounts for about 0.5% of ExodusPoint Capital Management LP’s portfolio, making the stock its 21st largest holding. ExodusPoint Capital Management LP owned approximately 0.11% of Becton, Dickinson and Company worth $74,119,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Bank of Jackson Hole Trust acquired a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth $25,000. Sierra Ocean LLC acquired a new stake in Becton, Dickinson and Company during the fourth quarter worth about $29,000. Picton Mahoney Asset Management increased its holdings in Becton, Dickinson and Company by 61.4% in the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 54 shares during the period. Hopwood Financial Services Inc. acquired a new position in shares of Becton, Dickinson and Company in the 4th quarter valued at approximately $39,000. Finally, Versant Capital Management Inc lifted its holdings in shares of Becton, Dickinson and Company by 54.1% during the 4th quarter. Versant Capital Management Inc now owns 208 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 73 shares during the period. Institutional investors own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Piper Sandler boosted their price objective on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, January 28th. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, Barclays lifted their target price on Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Buy” and a consensus target price of $278.29.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $226.55 on Thursday. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. The stock has a market cap of $65.05 billion, a PE ratio of 37.63, a PEG ratio of 1.63 and a beta of 0.35. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $251.99. The business has a 50-day simple moving average of $231.15 and a two-hundred day simple moving average of $231.58.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. Analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 31st. Investors of record on Monday, March 10th were paid a $1.04 dividend. The ex-dividend date of this dividend was Monday, March 10th. This represents a $4.16 annualized dividend and a dividend yield of 1.84%. Becton, Dickinson and Company’s dividend payout ratio is 69.10%.

Becton, Dickinson and Company declared that its Board of Directors has authorized a share repurchase program on Tuesday, January 28th that permits the company to buyback 10,000,000 shares. This buyback authorization permits the medical instruments supplier to buy shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 597 shares of the company’s stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $236.51, for a total value of $141,196.47. Following the sale, the executive vice president now directly owns 5,544 shares in the company, valued at $1,311,211.44. This represents a 9.72 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Richard Byrd sold 1,940 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $224.91, for a total transaction of $436,325.40. Following the transaction, the executive vice president now owns 7,411 shares of the company’s stock, valued at approximately $1,666,808.01. The trade was a 20.75 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 4,984 shares of company stock worth $1,147,865 over the last three months. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.